European Patent Office

T 2710/19 (Formulations of Pomalidomide / CELGENE) of 09.03.2022

European Case Law Identifier
ECLI:EP:BA:2022:T271019.20220309
Date of decision
9 March 2022
Case number
T 2710/19
Online on
14 March 2022
Petition for review of
-
Application number
10720107.1
Language of proceedings
English
Distribution
No distribution (D)
OJ versions
No OJ links found
Other decisions for this case
-
Abstracts for this decision
-
Application title
FORMULATIONS OF 4-AMINO-2-(2,6-DIOXOPIPERIDINE-3-YL)ISOINDOLINE-1,3-DIONE
Applicant name
Celgene Corporation
Opponent name
Teva Pharmaceutical Industries Ltd.
Generics [UK] Ltd
HGF Limited
STADA Arzneimittel AG
Hoffmann Eitle
Board
3.3.07
Headnote
-
Relevant legal provisions
European Patent Convention Art 113(2)
Keywords
Basis of decision - text or agreement to text withdrawn by patent proprietor
Basis of decision - patent revoked
Catchword
-
Cited cases
-
Citing cases
-

Order

For these reasons it is decided that:

1. The decision under appeal is set aside.

2. The patent is revoked.